Plural Bicyclo Ring Systems Each Having The Lactone Ring As One Of The Cyclos Patents (Class 549/284)
  • Publication number: 20150111888
    Abstract: The present invention provides a small compound targeting at TACC3. The present invention further provides a drug, particularly, an anticancer agent, comprising the small compound targeting at TACC3. A compound represented by the general formula (I) or a pharmaceutically acceptable salt, solvate, or ester derivative thereof binds to TACC3 and inhibits cell growth. Thus, these compounds can be used as drugs, particularly, anticancer agents.
    Type: Application
    Filed: April 30, 2013
    Publication date: April 23, 2015
    Inventors: Ryoji Yao, Hiroyuki Osada, Yasumitsu Kondoh
  • Patent number: 8729279
    Abstract: Agents or pharmaceutical compositions for promoting osteoblast differentiation include purified auraptene or coumarin analogs thereof represented by the following formula 1: wherein R1 represents a hydrogen, a hydroxy, a methoxy, a methyl, an ethyl, a propyl, a carboxyl, a carboxymethyl, or a carboxyethyl; R2 represents a hydrogen, a hydroxy, a methoxy, a methyl, an ethyl, a propyl, a carboxyl, a carboxymethyl, a carboxyethyl or a coumarinyl; R3 represents a hydrogen, a hydroxy, a methoxy, a methyl, an ethyl, a propyl, a carboxyl, a carboxymethyl or a carboxyethyl; and R4 represents a hydrogen, a C1-C15 liner or branched alkyl, an alkenyl, an alkadienyl or an alkatrienyl.
    Type: Grant
    Filed: February 28, 2011
    Date of Patent: May 20, 2014
    Assignee: Erina Co., Inc.
    Inventors: Je-Tae Woo, Ayaka Hibino, Takayuki Yonezawa, Midori Asai, Toshiaki Teruya, Byung-Yoon Cha, Kazuo Nagai
  • Publication number: 20130102796
    Abstract: Agents or pharmaceutical compositions for promoting osteoblast differentiation include purified auraptene or coumarin analogs thereof represented by the following formula 1: wherein R1 represents a hydrogen, a hydroxy, a methoxy, a methyl, an ethyl, a propyl, a carboxyl, a carboxymethyl, or a carboxyethyl; R2 represents a hydrogen, a hydroxy, a methoxy, a methyl, an ethyl, a propyl, a carboxyl, a carboxymethyl, a carboxyethyl or a coumarinyl; R3 represents a hydrogen, a hydroxy, a methoxy, a methyl, an ethyl, a propyl, a carboxyl, a carboxymethyl or a carboxyethyl; and R4 represents a hydrogen, a C1-C15 liner or branched alkyl, an alkenyl, an alkadienyl or an alkatrienyl.
    Type: Application
    Filed: February 28, 2011
    Publication date: April 25, 2013
    Applicant: ERINA CO., INC.
    Inventors: Je-Tae Woo, Ayaka Hibino, Takayuki Yonezawa, Midori Asai, Toshiaki Teruya, Byung-Yoon Cha, Kazuo Nagai
  • Patent number: 8337941
    Abstract: The present invention relates to compounds of the general structure: wherein Y is O, X is O, bond ? is absent and bond ? is present, or Y is H, X is CH, bond ? is present, and bond ? is absent; atom Z is a carbon and bonds ?, ? and ? are present, or is a nitrogen and bonds ?, ? and ? are absent; R1 is —H, —OH, —O—R7, —N(H)—R8, —N(H)—(CH2)n—NH2, —N(R9)(R10), or a piperazine cation; R2 is either covalently bound to R9, or is —H, or is covalently bound to R3 so as to form a substituted or unsubstituted pyrrole or R2 is covalently bound to R9 or R8 or R7; or R1 and R2 are covalently joined to form an aromatic ring; R3 is either covalently bound to R2 so as to form a pyrrole, or is, inter alia, —H, —OH, alkyl, or when Z is nitrogen R3 is ?O; R4 is, inter alia, —H, —OH, or —R11NH2; R5 is, inter alia, —H, —OH, or —R12NH2, and R6 is either is covalently bound to R10 or is —H, or R6 is covalently bound to R10 or R8 or R7.
    Type: Grant
    Filed: July 27, 2007
    Date of Patent: December 25, 2012
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Niko Gert Gubernator, Dalibor Sames, David Sulzer, Paul Vadola
  • Patent number: 8084625
    Abstract: The present invention provides a crosslinking agent which have photodegradable protective groups at two ends to crosslink double-stranded nucleic acid, a nucleic acid and a protein or a polypeptide, or proteins or polypeptides, in particular, double-stranded RNA; a method for crosslinking a double-stranded RNA or the like using the same; a method for regulating gene expression, which can control the expression of a target gene at an arbitrary timing and location; and a method for examining a gene function. According to the present invention, crosslinking between double-stranded nucleic acids between a nucleic acid and a protein or a polypeptide, or between proteins or polypeptides, in particular, between double-stranded RNA can be easily formed, and in addition, the crosslinking can also be easily removed, so that the expression of a target gene can be easily controlled at an arbitrary timing and location with high efficiency.
    Type: Grant
    Filed: February 27, 2006
    Date of Patent: December 27, 2011
    Assignee: Wako Pure Chemical Industries, Ltd.
    Inventors: Toshiaki Furuta, Natsuyo Imaizumi
  • Patent number: 8067461
    Abstract: Compounds of Formula I: wherein R1, R2, M, Q and n are as defined herein, are useful as antiproliferative agents including, for example, as anticancer agents.
    Type: Grant
    Filed: June 2, 2006
    Date of Patent: November 29, 2011
    Assignee: Temple University-Of The Commonwealth System of Higher Education
    Inventors: M. V. Ramana Reddy, E. Premkumar Reddy
  • Publication number: 20090233232
    Abstract: A photosensitive compound has two or more structural units, in a molecule, represented by the following general formula (1): wherein R1 to R5 are selected from the group consisting of hydrogen atom, halogen atom, alkyl group, alkoxy group, acetoxy group, phenyl group, naphthyl group, and alkyl group in which a part or all of hydrogen atoms are substituted with fluorine atom; and X is a substituted or unsubstituted phenylene group or a substituted or unsubstituted naphthylene group.
    Type: Application
    Filed: May 19, 2009
    Publication date: September 17, 2009
    Applicant: CANON KABUSHIKI KAISHA
    Inventors: Toshiki Ito, Takako Yamaguchi
  • Patent number: 7569694
    Abstract: Provided are an organic electroluminescent device having better performances in luminous efficiency, device life and driving voltage, a display unit equipped with the same and a lighting instrument equipped with the same. The organic electroluminescent device comprises an electron transport layer containing a specific arylamine-substituted coumarin compound.
    Type: Grant
    Filed: January 29, 2007
    Date of Patent: August 4, 2009
    Assignees: Chisso Corporation, Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo
    Inventors: Toshihiro Koike, Manabu Uchida, Makoto Satsuki, Makoto Fujiwara, Ayashi Noguchi
  • Patent number: 7514158
    Abstract: A method for producing a coumarin compound represented by Formula 1, which comprises a step of reacting a coumarin compound represented by Formula 1 with a compound having an aldehyde group and an activated methylene group; luminous agents for organic EL elements and organic EL elements which all comprise the coumarin compound; and displaying panels and information displaying apparatuses using the organic EL elements: ø(Z)m??Formula 1 wherein in Formula 1, ø is an aromatic ring, heterocycle, or a combination thereof, each Z is the same or a different coumarin group represented by Formula 2; and m is an integer of two or more;
    Type: Grant
    Filed: December 10, 2002
    Date of Patent: April 7, 2009
    Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo
    Inventors: Makoto Satsuki, Makoto Fujiwara, Natsuko Ishida, Sadaharu Suga, Hisayoshi Fujikawa, Hisato Takeuchi, Yasunori Taga
  • Publication number: 20090023140
    Abstract: The present invention provides a crosslinking agent which have photodegradable protective groups at two ends to crosslink double-stranded nucleic acid, a nucleic acid and a protein or a polypeptide, or proteins or polypeptides, in particular, double-stranded RNA; a method for crosslinking a double-stranded RNA or the like using the same; a method for regulating gene expression, which can control the expression of a target gene at an arbitrary timing and location; and a method for examining a gene function. According to the present invention, crosslinking between double-stranded nucleic acids between a nucleic acid and a protein or a polypeptide, or between proteins or polypeptides, in particular, between double-stranded RNA can be easily formed, and in addition, the crosslinking can also be easily removed, so that the expression of a target gene can be easily controlled at an arbitrary timing and location with high efficiency.
    Type: Application
    Filed: February 27, 2006
    Publication date: January 22, 2009
    Applicant: WAKO PURE CHEMICAL INDUSTRIES, LTD.
    Inventors: Toshiaki Furuta, Natsuyo Imaizumi
  • Publication number: 20070176544
    Abstract: Provided are an organic electroluminescent device having better performances in luminous efficiency, device life and driving voltage, a display unit equipped with the same and a lighting instrument equipped with the same. The organic electroluminescent device comprises an electron transport layer containing a specific arylamine-substituted coumarin compound.
    Type: Application
    Filed: January 29, 2007
    Publication date: August 2, 2007
    Inventors: Toshihiro Koike, Manabu Uchida, Makoto Satsuki, Makoto Fujiwara, Ayashi Noguchi
  • Patent number: 7148253
    Abstract: 4-Thio substituted coumarin derivatives, 4,5-dithio substituted coumarin derivatives, and coumarin dimers are provided, as well as processes for their preparation. The invention also provides a method and composition for the treatment of hepatitis C virus (HCV) by adiministering 4-thio substituted coumarin derivatives, 4,5-dithio substituted coumarin derivatives, and coumarin dimers.
    Type: Grant
    Filed: January 6, 2004
    Date of Patent: December 12, 2006
    Assignee: XTL Biopharmaceuticals Ltd.
    Inventors: Jie Wu, Zhen Yang, Reza Fathi, Qiang Zhu
  • Publication number: 20040220258
    Abstract: This invention is drawn to compounds which are more easily metabolized by the metabolic drug detoxification systems. Particularly, warfarin analogs which have been designed to include esters within the structure of the compounds are taught. The invention teaches methods of reducing the toxicity of drugs comprising the introduction of ester groups into drugs during the synthesis of the drug. This invention is also drawn to methods of treating coagulation disorders comprising the administration of compounds which have been designed to be metabolized by serum or intracellular hydrolases and esterases. Pharmaceutical compositions of the ester containing warfarin, analogs are also taught.
    Type: Application
    Filed: April 8, 2004
    Publication date: November 4, 2004
    Inventors: Pascal Druzgala, Xiaoming Zhang, Jurg R. Pfister
  • Patent number: 6770385
    Abstract: A fluorescent compound, suitable for use in an active layer of an organic light-emitting device and exhibiting both good luminescence and excellent thermal stability, which has the structure wherein R is substituted or unsubstituted alkyl; wherein Ar2 is optionally present; and wherein Ar1, Ar2, and Ar3 are independently each a substituted or unsubstituted aryl group.
    Type: Grant
    Filed: January 9, 2002
    Date of Patent: August 3, 2004
    Assignee: Canon Inc.
    Inventors: Jian Ping Chen, Travis P. S. Thoms, Bing R. Hsieh
  • Patent number: 6703514
    Abstract: 4-thio substituted coumarin derivatives and coumarin dimers are provided, as well as processes for their preparation. A synthetic process for the preparation of 4-thio substituted coumarin derivatives is provided using mild reaction conditions, which maintains a high substituent tolerance and is appropriate for use in solid phase syntheses for producing a library of 4-thio substituted coumarin derivatives for biological screening.
    Type: Grant
    Filed: May 13, 2003
    Date of Patent: March 9, 2004
    Assignee: Vivo Quest, Inc.
    Inventors: Jie Wu, Zhen Yang, Reza Fathi, Qiang Zhu, Lisha Wang
  • Publication number: 20040002538
    Abstract: 4-thio substituted coumarin derivatives and coumarin dimers are provided, as well as processes for their preparation. A synthetic process for the preparation of 4-thio substituted coumarin derivatives is provided using mild reaction conditions, which maintains a high substituent tolerance and is appropriate for use in solid phase syntheses for producing a library of 4-thio substituted coumarin derivatives for biological screening.
    Type: Application
    Filed: May 13, 2003
    Publication date: January 1, 2004
    Inventors: Jie Wu, Zhen Yang, Reza Fathi, Qiang Zhu, Lisha Wang
  • Patent number: 6589976
    Abstract: The invention relates to novel spirocyclic phenylketoenols of the formula in which Het represents one of the groups  in which Q represents and X, Y, Z, m, n, R6, R9, R10 and R11 are each as defined in the description, to a plurality of processes and intermediates for their preparation and to their use as pesticides and herbicides.
    Type: Grant
    Filed: March 21, 2000
    Date of Patent: July 8, 2003
    Assignee: Bayer Aktiengesellschaft
    Inventors: Reiner Fischer, Thomas Bretschneider, Christoph Erdelen, Ulrike Wachendorff-Neumann, Markus Dollinger, Andreas Turberg
  • Patent number: 6455579
    Abstract: Disclosed are pyran derivatives, which have distinctive sensitivity to visible light and distinctive luminous ability. The derivatives are useful in photopolymerization, electroluminescence, and dye lasers, and are obtainable through a step of reacting a compound having a 4-cyanomethylene-2-methyl-4H-pyran skeleton with a compound having a 3-formylcoumarin skeleton.
    Type: Grant
    Filed: November 9, 2000
    Date of Patent: September 24, 2002
    Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo
    Inventors: Makoto Satsuki, Akira Shinpo, Yasuyo Ooga, Sadaharu Suga, Atsushi Oda, Hiroshi Tada, Yoshikazu Sakaguchi
  • Patent number: 6344334
    Abstract: Method for identifying a drug lead compound that inhibits binding of target bioogical molecules (TBM) by contacting TBM with members of a library of candidate cross-linked target binding fragments (CXBF), each CXBF having at least two candidate target bindig fragments (CTBF), which are inhibitors of binding, linked to a cross-linker, and selecting CXBF that inhibit the binding of the TBM to a greater extent than either of the individual CTBF linked to said cross-linker, wherein the library of CXBF is produced by: (a) screening a population of CTBF capable of being chemically cross-linked by a cross-linker to identify a subpopulation of the CTBF that inhibit binding of the TBM; and (b) chemically cross-linking members of the subpopulation of CTBF or structurally related analogs thereof with a cross-linker to provide a library of CXBF, wherein at least one linking group comprises an oxime ether linking group.
    Type: Grant
    Filed: March 26, 1999
    Date of Patent: February 5, 2002
    Assignee: The Regents of the University of California
    Inventors: Jonathan A. Ellman, Ingrid Choong
  • Patent number: 6344330
    Abstract: The present invention is directed to novel methods for identifying small molecule ligands that are capable of binding with high affinity to a biological target molecule of interest. High affinity binding ligands identified by the described methods find use, for example, as small molecule lead compounds that may they themselves be, or may give rise to, novel therapeutic drugs. More specifically, the subject invention is directed to methods for identifying a ligand that binds to a target biological molecule of interest, wherein a population of small organic compounds are selected and then “pre-screened” to identify those that are capable of binding to the molecular target.
    Type: Grant
    Filed: March 27, 1998
    Date of Patent: February 5, 2002
    Assignee: The Regents of the University of California
    Inventors: Jonathan A. Ellman, Ingrid Choong
  • Patent number: 6291518
    Abstract: The present invention relates to novel hydroxy and polyhydroxy derivatives of coumarin fused with dialdehydes and aldehyde acids of the general formulae I, II, III and IV: wherein R1=R2=4-hydroxycoumarin; R1=R2=4,7-dihydroxycoumarin; R1=R2=4,5,7-trihydroxycoumarin; R1=4-hydroxycoumarin, R2=—CH(OH)CH3. An object of the invention are also processes for the preparation of hydroxy and polyhydroxy derivatives of coumarin fused with dialdehydes and aldehyde acids, and the antiviral action thereof. Novel hydroxy and polyhydroxy derivatives of coumarin according to the present invention exhibit antiviral action against HIV-1 virus.
    Type: Grant
    Filed: January 3, 2000
    Date of Patent: September 18, 2001
    Assignee: Pliva farmaceutska, kemijska, prehrambena i kozmeticka industrija, dionicko drustvo
    Inventors: Mladen Trkovnik, Zrinka Ivezić
  • Patent number: 6100409
    Abstract: The present invention relates to novel hydroxy and polyhydroxy derivatives of coumarin fused with dialdehydes and aldehyde acids of the general formulae I, II, III and IV: ##STR1## wherein R.sup.1 =R.sup.2 =4-hydroxycoumarin;R.sup.1 =R.sup.2 =4,7-dihydroxycoumarin;R.sup.1 =R.sup.2 =4,5,7-trihydroxycoumarin;R.sup.1 =4-hydroxycoumarin, R.sup.2 =--CH(OH)CH.sub.3.An object of the invention are also processes for the preparation of hydroxy and polyhydroxy derivatives of coumarin fused with dialdehydes and aldehyde acids, and the antiviral action thereof.Novel hydroxy and polyhydroxy derivatives of coumarin according to the present invention exhibit antiviral action against HIV-1 virus.
    Type: Grant
    Filed: October 2, 1998
    Date of Patent: August 8, 2000
    Assignee: PLIVA farmaceutska, kemijska, prehrambena i kozmeticka industrija dionicko drustvo
    Inventors: Mladen Trkovnik, Zrinka Ivezic
  • Patent number: 6034121
    Abstract: Compounds of the formula ##STR1## where one of Z and Y is CO and the other is C--W--R.sup.2 and the dotted line indicates a double bond is present where necessary to meet valency requirements, W is O, S(O).sub.n, N(R.sup.3), N(R.sup.3)(R.sup.4), N(R.sup.3)O or ON(R.sup.3); R.sup.1 is hydrogen, or an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, phenyl or heterocyclyl group; R.sup.2, R.sup.3 and R.sup.4, which may be the same or different, are as defined above for R.sup.1, or are acyl, or R.sup.2 and R.sup.3 or R.sup.2 and R.sup.4 or R.sup.3 and R.sup.4 together with the nitrogen or oxygen to which they are attached form an optionally substituted ring which may contain other hetero atoms; each X, which may be the same as or different from any other X, is halogen, CN, NO.sub.2, SF.sub.5, B(OH).sub.2, triakylsilyl or a group E, OE or S(O).sub.n E where E is a group as defined hereinbefore for R.sup.
    Type: Grant
    Filed: April 1, 1998
    Date of Patent: March 7, 2000
    Assignee: Agrevo UK Limited
    Inventors: Mary Josephine O'Mahony, Peter John West, Jacqueline Anne MacRitchie, Stephen David Lindell, Peter Millward
  • Patent number: 5856479
    Abstract: Using the fluorescent group-containing carbodiimide compound represented-by the following formula (I) as the label and the like in the nucleic acid detection method, immunoassay, or chemiluminescence assay, labeling can be made efficiently for a short time, a nucleic acid derived from nature can be labelled, and highly sensitive assay is enabled.B--Y.sup.3 --N.dbd.C.dbd.N--Y.sup.2 --W--Y.sup.1 --?A!.sub.n --F(I)wherein F represents a fluorescent group;A represents a moiety selected from the group consisting of --CH.sub.2 --, --NHCO--, --CONH--, --O--, --S--, --NR-- wherein R is an alkyl group, --COO--, --OCO--, --NHSO.sub.2 --, and --SO.sub.2 NH--;n is 0 or 1;W represents a direct bond or a quaternary ammonium group;Y.sup.1, Y.sup.2 and Y.sup.3 each represents an alkylene group which may have a functional group in its main chain; andB represents H or a monovalent organic group which may be the same as or different from that represented by --W--Y.sup.1 --?A!.sub.n --F.
    Type: Grant
    Filed: May 16, 1997
    Date of Patent: January 5, 1999
    Assignee: Nisshinbo Industries, Inc.
    Inventors: Osamu Suzuki, Gen Masuda, Namiko Shiohata, Kazuko Matsumoto
  • Patent number: 5756740
    Abstract: A process for the preparation of photographic binary sensitizing dyes, which comprise two separate, nonconjugated chromophores, one of which has the capability of adsorbing to a silver halide grain surface, the other of which is substantially non-adsorbing to silver halide. The process comprises reacting two dye compounds in a solvent in the presence of a 2-halo-1-alkylpyridinium salt and a 4-dialkylaminopyridine.
    Type: Grant
    Filed: April 8, 1992
    Date of Patent: May 26, 1998
    Assignee: Eastman Kodak Company
    Inventors: Lal Chand Vishwakarma, Chin Hsin Chen
  • Patent number: 5646164
    Abstract: The present inventors have discovered three classes of novel .alpha.-methylene-.gamma.-butyrolactones with excellent antiplatelet activity. As a result of intensive studies, it has been found that compounds represented by the formula I-III are potent inhibitors of platelet aggregation. ##STR1## For the formula I, R.sub.1 is a methyl, a phenyl group optionally substituted with one or two group selected from halide, (C.sub.1 -C.sub.4) alkyl, (C.sub.1 -C.sub.4) alkoxy, phenyl, nitro, amino.For the formula II, R.sub.1 is a methyl, a phenyl group optionally substituted with one or two group selected from halide, (C.sub.1 -C.sub.4) alkyl, (C.sub.1 -C.sub.4) alkoxy, phenyl, nitro, amino; R.sub.2 represents hydrogen, halide, (C.sub.1 -C.sub.4) alkyl, phenyl, nitro, amino; R.sub.3 represents hydrogen, halide, (C.sub.1 -C.sub.4) alkyl, phenyl, nitro, amino.For the formula III, R.sub.1 is a methyl, a phenyl group optionally substituted with one or two group selected from halide, (C.sub.1 -C.sub.4) alkyl, (C.sub.1 -C.
    Type: Grant
    Filed: November 14, 1995
    Date of Patent: July 8, 1997
    Assignee: National Science Council
    Inventors: Cherng-Chyi Tzeng, Yeh-Long Chen, Tai-Chi Wang, Che-Ming Teng
  • Patent number: 5116869
    Abstract: 2-Substituted-2-cyclopentenones represented by the formula (I): ##STR1## wherein A is a hydroxyl group or ##STR2## and B is a hydrogen atom or A and B are bonded together to form one bonding arm;R.sup.1 represents a substituted or unsubstituted hydrocarbon group having 1 to 10 carbon atoms;R.sup.2 represents a substituted or unsubstituted aliphatic hydrocarbon group having 1 to 10 carbon atoms;R.sup.3 represents a substituted or unsubstituted aliphatic hydrocarbon group having 1 to 10 carbon atoms; wherein,when R.sup.3 is a single bond bonded to the cyclopentene skeleton, X represents a hydrogen atom, a hydroxyl group or a protected hydroxyl group; andwhen R.sup.3 is a double bond bonded to the pentene skeleton, X represents a bonding arm constituting a part of said double bond; andm and n independently represent 0, 1 or 2.
    Type: Grant
    Filed: September 3, 1991
    Date of Patent: May 26, 1992
    Assignee: Teijin Limited
    Inventors: Satoshi Sugiura, Atsuo Hazato, Toru Minoshima, Yoshinori Kato, Yasuko Koshihara, Seizi Kurozumi
  • Patent number: 4547579
    Abstract: There are described novel dyes of the formulae ##STR1## in which R.sub.1 and R.sub.2 independently of one another are each hydrogen, unsubstituted or substituted alkyl, cycloalkyl, aralkyl or aryl, and R.sub.1 and R.sub.2 together with the nitrogen atom, and optionally with the inclusion of further hetero atoms, can also form a 5- to 7-membered heterocycle, or one of the radicals R.sub.1 or R.sub.2 can be linked with the carbon atoms, in the o-position with respect to the amino group, of the ring A to form a fused-on, saturated, unsubstituted or substituted 5- or 6- membered ring,X is .dbd.NR.sub.3, .dbd.NCOR.sub.4, ##STR2## .dbd.NH or .dbd.O, wherein R.sub.3 is alkyl or unsubstituted or substituted phenyl,R.sub.4 is unsubstituted or substituted alkyl, aralkyl, aryl, vinyl, alkoxy, phenoxy or amino, andR.sub.5 is cyano, carbalkoxy, or unsubstituted or substituted carbonamide, andR.sub.
    Type: Grant
    Filed: September 30, 1982
    Date of Patent: October 15, 1985
    Assignee: Ciba-Geigy Corporation
    Inventor: Peter Mockli